PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Neuron. Author manuscript; available in PMC 2010 July 16.
Published in final edited form as:
PMCID: PMC2758064
NIHMSID: NIHMS122685

GOSPEL: A novel neuroprotective protein that binds to GAPDH upon S-nitrosylation

Abstract

We recently reported a novel cell death cascade whereby cellular stressors activate nitric oxide formation leading to S-nitrosylation of GAPDH that binds to Siah and translocates to the nucleus. The nuclear GAPDH/Siah complex augments p300/CBP-associated acetylation of nuclear proteins, including p53, which mediate cell death. We report a novel 52 kDa cytosolic protein, GOSPEL, which physiologically binds GAPDH, in competition with Siah, retaining GAPDH in the cytosol and preventing its nuclear translocation. GOSPEL is neuroprotective, as its overexpression prevents NMDA-glutamate excitotoxicity while its depletion enhances death in primary neuron cultures. S-nitrosylation of GOSPEL at cysteine-47 enhances GAPDH-GOSPEL binding and the neuroprotective actions of GOSPEL. In intact mice virally delivered GOSPEL selectively diminishes NMDA neurotoxicity. Thus, GOSPEL may physiologically regulate the viability of neurons and other cells.

INTRODUCTION

Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is generally regarded as a housekeeping glycolytic enzyme. However, several studies implicate GAPDH in cell signaling (Chuang et al., 2005; Hara et al., 2006a; Sirover, 1999, 2005). We recently described a signaling system influencing cell death whereby diverse cell stressors activate inducible or neuronal nitric oxide synthase (NOS) leading to the generation of nitric oxide (NO), which S-nitrosylates GAPDH (Benhar and Stamler, 2005; Hara et al., 2005; Hara et al., 2006a). S-nitrosylation abolishes catalytic activity of the enzyme and confers upon it the ability to bind to Siah, an E3-ubiquitin-ligase. The nuclear localization signal of Siah elicits nuclear translocation of GAPDH. In the nucleus GAPDH binds to the protein acetyltransferase p300/CBP, enhancing its acetylation of various targets, including p53, with subsequent augmentation of cytotoxicity (Sen et al., 2008).

This signaling cascade appears to mediate the cytoprotective actions of the monoamine oxidase inhibitor R-(-)-deprenyl (selegiline, hereafter designated deprenyl) as well as nonmonoamine oxidase inhibiting derivatives (Tatton et al., 2003; Waldmeier et al., 2000). At low nanomolar concentrations these drugs prevent the S-nitrosylation of GAPDH, its binding to Siah, and nuclear translocation, with neuroprotective actions in cells and rodent models of Parkinsonism at drug doses as low as 0.01 mg/kg (Hara et al., 2006b). Disruption of the NO-GAPDH-Siah cascade also blocks neurotoxicity elicited by excess activation of NMDA (N-methyl-D-aspartate) receptors and mutant Huntingtin (Bae et al., 2006; Hara et al., 2005).

In the present study we report a novel protein interactor of GAPDH, designated GOSPEL (GAPDH's competitor Of Siah Protein Enhances Life). Cell stress elicits S-nitrosylation of GOSPEL, enabling it to bind GAPDH in competition with Siah. The binding of GOSPEL to GAPDH prevents nuclear translocation of GAPDH and prevents cyto/neurotoxicity. In intact mice GOSPEL overexpression in the cerebral cortex reduces NMDA neurotoxicity. This neuroprotection reflects GOSPEL's binding to GAPDH, as mutant GOSPEL that cannot bind GAPDH displays greater neurotoxicity. The competition between GOSPEL and Siah for GAPDH binding may reflect a regulatory system that maintains cellular homeostasis in response to stressors.

RESULTS

Identification of GOSPEL

In a yeast two-hybrid analysis with the N-terminal 150 amino acids of GAPDH and a rat hippocampal cDNA library, we identified 27 positive interactors out of 106 clones, 25 of which represented various fragments of GAPDH. This presumably reflects the tendency for this protein to form homo-tetramers (Carlile et al., 2000). The two non-GAPDH interactors are a fragment of GOSPEL and an uncharacterized EST clone (Figure 1A). By contrast, yeast two-hybrid studies employing the C-terminal 183 amino acids of GAPDH identify Siah, but not GOSPEL (Hara et al., 2005). After cDNA library screening, we identified the entire coding frame of GOSPEL. GOSPEL contains 406 amino acids with no obvious recognition motifs except for a four amino acid stretch of glutamines (Supplementary Figure 1A). The intron-exon structure of GOSPEL suggests the possibility of alternatively spliced isoforms (Supplementary Figure 1B), though there is high sequence conservation between rodents and humans (Supplementary Figure 1C).

Figure 1
Identification and characterization of GOSPEL

Northern blot analysis reveals GOSPEL expression highest in heart, skeletal muscle, brain, and lung (Figure 1B). Western blot analysis, employing an affinity-purified polyclonal antibody developed against a recombinant GST-fused GOSPEL, reveals a similar tissue distribution to that shown by Northern blotting (Figure 1C). In brain, heart and skeletal muscle, Western blots show an apparent molecular weight for GOSPEL of about 52 kDa, while in lung the apparent size is somewhat greater, about 55 kDa. Interestingly, tissues such as brain, heart, lung and skeletal muscle, that are most enriched in GOSPEL, also contain highest levels of GAPDH. In brain, GOSPEL is widely expressed in neurons, especially abundant in neurons that contain high levels of GAPDH, such as Purkinje cells in the cerebellum as well as pyramidal cells of CA1-3 and granule cells of the dentate gyrus in the hippocampus (Figure 1D).

We examined the intracellular localization of GOSPEL by immunofluorescent cell staining with confocal microscopy (Figure 1E). Overexpressed GOSPEL in HEK293T cells and endogenous GOSPEL in PC12 cells are both predominantly cytosolic.

GOSPEL S-nitrosylation is required for binding GAPDH

We mapped binding sites in GAPDH and GOSPEL by performing selective deletions followed by immunoprecipitation from HEK293 cells (Figure 2A, B; Supplementary Figure 2A, B). We identified amino acids 160-200 of GOSPEL as critical for binding to GAPDH. In GAPDH a domain comprising amino acids 80-120 is required for binding to GOSPEL.

Figure 2
GOSPEL-GAPDH protein interaction

To determine the importance of S-nitrosylation for the interaction of these proteins, we examined the binding of GOSPEL to GAPDH in extracts of NMDA-treated or no treated cerebral cortical cultures prepared from wild-type or nNOS knockout mice (Figure 2C; Supplementary Figure 2C). It has been demonstrated that NMDA stimulation of cerebral cortical neurons elicits the generation of NO from nNOS, leading to S-nitrosylation of various proteins, including GAPDH (Hara et al., 2005; Takahashi et al., 2007). Low level of GAPDH-GOSPEL binding is detected in the absence of NMDA treatment. The NMDA-augmented GAPDH-GOSPEL protein interaction is markedly reduced in nNOS knockout cultures. To ascertain whether the requirement for NO involves GOSPEL, we examined whether GOSPEL can be S-nitrosylated. In cerebral cortical cultures stimulated with NMDA, biotin-switch assays reveal robust endogenous S-nitrosylation of GOSPEL, which is absent in nNOS knockout cultures (Figure 2D). The S-nitrosylation of GOSPEL and GAPDH is time-dependent (Figure 2E). Following NMDA treatment, S-nitrosylated GOSPEL (SNO-GOSPEL) is detected as early as 3 h and peaks at 9-16 h, while GAPDH S-nitrosylation is not evident till 6 h and continues to increase between 9 and 16 h. We wondered whether the S-nitrosylation of GOSPEL might reflect transnitrosylation from GAPDH. This is unlikely, as incubation of S-nitrosylated GAPDH with GOSPEL fails to elicit augmented S-nitrosylation of GOSPEL (Supplementary Figure 2D).

GOSPEL contains a single cysteine at position 47 (C47), which conforms to an S-nitrosylation motif, as the glutamate immediately following C47 resembles the pattern for numerous S-nitrosylated proteins (Kim et al., 1999) including hemoglobin, ras, NMDA-receptor and dynamin. S-nitrosylation of GOSPEL is abolished by replacing the cysteine with serine (GOSPEL-C47S), indicating that this single amino acid is the site for S-nitrosylation of GOSPEL (Figure 2F). S-nitrosylation at C47 is crucial for GOSPEL binding to GAPDH, as their binding is greatly reduced for GOSPEL-C47S in HEK293 cells (Figure 2G). We have confirmed the importance of S-nitrosylation at C47 for GOSPEL-GAPDH interaction utilizing in vitro binding of the purified proteins (Supplementary Figure 3A). GAPDH S-nitrosylation occurs exclusively on C150 (Hara et al., 2005). The GAPDH-C150S mutant, which cannot be S-nitrosylated, binds significantly less to GOSPEL than the wild-type protein, in HEK293 cells (Supplementary Figure 3B, C). Therefore, S-nitrosylation of both GAPDH and GOSPEL is crucial for their binding (Supplementary Figure 3C). Of note, GOSPEL, SNO-GOSPEL, and Siah do not influence the catalytic activity of wild-type GAPDH (Supplementary Figure 3D, E).

Competition by GOSPEL and Siah for GAPDH binding

Interaction of GAPDH and Siah occurs without S-nitrosylation of Siah, but is augmented by S-nitrosylation of GAPDH. As both Siah and SNO-GOSPEL can bind to S-nitrosylated GAPDH (SNO-GAPDH), we compared the potencies of Siah and SNO-GOSPEL in competing for binding to SNO-GAPDH (Figure 3A, B). SNO-GOSPEL potently inhibits binding of SNO-GAPDH and Siah with an IC50 of about 10 nM. The inhibition curve is steep with a decrease of maximal to minimal binding occurring over a 3-fold increase in SNO-GOSPEL concentration. Siah is less potent in inhibiting the binding of SNO-GAPDH and SNO-GOSPEL with an IC50 of about 100 nM. The inhibition curve is also steep with maximal to minimal binding evident over a 4-fold increase in Siah concentration. Different portions of GAPDH respectively bind to GOSPEL and Siah (Figures 1A and and2B).2B). To determine whether GOSPEL and Siah nonetheless compete for binding to GAPDH, we overexpressed GOSPEL, Siah and GAPDH in HEK293 cells (Figure 3C). Overexpression of GOSPEL markedly diminishes the binding of GAPDH to Siah in the presence of the NO-donor GSNO. Moreover, purified GST-GOSPEL blocks protein interactions of GAPDH and His-Siah in the presence of GSNO (Supplementary Figure 4).

Figure 3
GOSPEL-GAPDH binding prevents GAPDH-Siah interaction

NMDA also enhances the GAPDH-GOSPEL interactions more rapidly than GAPDH-Siah binding (Figure 3D). GAPDH-GOSPEL binding is detectable under basal conditions with increases evident by 3 h after NMDA. By contrast, GAPDH-Siah binding is absent basally and is not detected until 9 h after NMDA. The differential kinetics of GAPDH-GOSPEL binding from GAPDH-Siah binding may reflect more rapid S-nitrosylation of GOSPEL (required for GAPDH-GOSPEL binding) than of GAPDH (required for GAPDH-Siah binding) (Figure 2E).

GOSPEL prevents the nuclear translocation of GAPDH

To ascertain whether endogenous GOSPEL modulates GAPDH-Siah interactions, we depleted endogenous GOSPEL from primary neuronal cultures of cerebral cortex utilizing RNA interference (RNAi) conveyed by a lentivirus. To rule out the possibility of “off-target” effects of RNAi, we carried out quantitative real-time PCR for 2′5′-oligoadenylate synthetase (OAS1), which monitors such off-target effects (Supplementary Figure 5A). The control and GOSPEL RNAi treatment has no influence on the levels of OAS1 mRNA. Furthermore, such RNAi treatment does not affect the levels of nNOS and NO generated in response to NMDA treatment in neurons (Supplementary Figure 5B, C, D). The RNAi to GOSPEL reduces the endogenous protein level by 90% (Supplementary Figure 6A, B). NMDA-elicited GAPDH-Siah binding is markedly augmented in GOSPEL depleted cultures, establishing that GOSPEL inhibits this interaction (Figure 4A).

Figure 4
GOSPEL-GAPDH binding prevents GAPDH-Siah interaction

Since Siah mediates nuclear translocation of GAPDH, we wondered whether GOSPEL prevents such translocation and retains GAPDH in the cytosol. Treatment of HEK293 cells with GSNO, as previously reported, leads to substantial accumulation of GAPDH in the nucleus (Hara et al., 2005). Overexpression of GOSPEL diminishes the nuclear localization of GAPDH (Figure 4B). Endogenous GOSPEL also regulates the NMDA-elicited nuclear translocation of GAPDH, as depletion of GOSPEL by RNAi markedly enhances nuclear GAPDH levels in neuronal cultures (Figure 4C; Supplementary Figure 6C).

GOSPEL diminishes NMDA neurotoxicity by preventing GAPDH-Siah binding

We previously demonstrated that NMDA stimulation of cerebellar granule neurons elicits NO generation from nNOS and S-nitrosylation of GAPDH, which translocates to the nucleus together with Siah and elicits neurotoxicity (Hara et al., 2005; Hara et al., 2006b). We wondered whether the prevention of GAPDH-Siah binding by GOSPEL impacts such neurotoxicity. Accordingly, we examined neurotoxicity in primary cerebellar granule neurons following NMDA treatment (Figure 5A). Overexpression of GOSPEL almost completely prevents the 75% decrease in neuronal viability elicited by NMDA treatment. Deletion of the N-terminal 200 amino acids of GOSPEL (GOSPEL-ΔN200), which prevents binding to GAPDH, abrogates the protective effect of GOSPEL. By contrast, deleting the N-terminal 160 amino acids (GOSPEL-ΔN160), which does not impair GOSPEL-GAPDH binding, preserves the protective actions of GOSPEL. S-nitrosylation of GOSPEL, which is crucial for binding to GAPDH, is also required for the neuroprotective actions of GOSPEL. Thus, GOSPEL-C47S, which cannot be S-nitrosylated and which does not bind to GAPDH robustly, fails to exert a strong neuroprotective action.

Figure 5
Modulation of NMDA-mediated neurotoxicity by GOSPEL

To determine whether endogenous GOSPEL influences neurotoxicity, we employed lentivirus-mediated RNAi to deplete endogenous GOSPEL in primary cerebellar granular cells and cortical neurons. In both cell types we examined NMDA-nNOS-triggered excitotoxicity, a widely employed model of neurotoxicity (Bonfoco et al., 1995; Dawson et al., 1996), in which GAPDH-Siah is a mediator (Hara et al., 2005; Hara et al., 2006b). Both at 12 and 24 h following NMDA treatment, cell survival is substantially reduced in GOSPEL depleted cultures (Figure 5B, C; Supplementary Figure 7A, 7B)

GOSPEL is neuroprotective in intact mice

Earlier we demonstrated that treatment with the neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) augments the binding of GAPDH to Siah in mouse corpus striatum (Hara et al., 2006b; Sen et al., 2008). Utilizing a similar paradigm, we show that MPTP treatment stimulates striatal S-nitrosylation of both GAPDH and GOSPEL (Supplementary Figure 8A). MPTP treatment also stimulates the binding of GAPDH-GOSPEL as well as GAPDH-Siah, with the increased interaction of GAPDH-GOSPEL occurring earlier than that of GAPDH-Siah (Supplementary Figure 8B).

To determine whether neuroprotective actions of GOSPEL are evident in intact mice, we utilized a viral vector system that delivers into the cerebral cortex wild-type GOSPEL and GOSPEL lacking the N-terminal 200 amino acids (GOSPEL-ΔN200, which does not bind GAPDH). The two GOSPEL constructs display similar levels of expression in the cerebral cortex monitored by Western blotting (Figure 6A) and immunohistochemical staining (Figure 6B). Neurotoxicity was elicited by direct injection of NMDA into the cerebral cortex (Figure 6C, D). NMDA-induced lesions in brains of GOSPEL-overexpressed mice are about 30% smaller than in those injected with GOSPEL-ΔN200. Thus, GOSPEL overexpression in the cerebral cortex leads to selective diminution of NMDA neurotoxicity in vivo. The neuroprotective influence of GOSPEL is attributable to its binding to GAPDH, as a mutant GOSPEL which does not bind GAPDH displays diminished neuroprotective action.

Figure 6
Prevention of NMDA induced toxicity in brains expressing wild-type GOSPEL but not GOSPEL-ΔN200 deficient in GAPDH binding

DISCUSSION

In this study we report a novel protein, GOSPEL, which physiologically binds GAPDH. S-nitrosylation of GOSPEL augments for GAPDH-GOSPEL binding, which competes with the interaction of GAPDH with Siah. This competition prevents the nuclear translocation of GAPDH and associated neurotoxicity (Supplementary Figure 9).

GOSPEL is a hydrophilic protein that contains 406 amino acids and appears to be exclusively cytosolic. It lacks obvious functional motifs such as nuclear export and import signals. GOSPEL mRNA and protein levels are highest levels in organs most enriched in GAPDH, such as brain, heart, lung and skeletal muscle. This is consistent with the notion that GOSPEL physiologically modulates GAPDH functions. By contrast Siah levels are similar in all organs examined.

GOSPEL retains GAPDH in cytosol, as its depletion augments the nuclear translocation of GAPDH that is associated with cell stress. GOSPEL's neuroprotective actions are robust, as the 75% reduction in viability of cortical neurons elicited by NMDA is reversed by overexpression of GOSPEL in a fashion indicating that its neuroprotective actions derive from its binding GAPDH. In turn, depletion of GOSPEL increases NMDA neurotoxicity.

S-nitrosylation in response to NMDA occurs more rapidly for GOSPEL than GAPDH. Conceivably, this is relevant to the dynamics of cellular responses to nitrosative stress. Thus, perhaps a more rapid initiation of cytoprotective (GOSPEL S-nitrosylation) than cytotoxic (GAPDH S-nitrosylation) mechanisms reflects the cell's approach to coping with nitrosative stress. The more rapid response of GOSPEL to NO suggests that it may have physiologic as well as pathophysiologic functions.

Deprenyl and related neuroprotective drugs very potently prevent GAPDH S-nitrosylation and its binding to Siah (Hara et al., 2006b). We speculate that GOSPEL and deprenyl act at similar sites on GAPDH. Thus, GOSPEL binds to amino acids 80-120 of GAPDH, which contains the Rossman fold (Nagy and Rigby, 1995). The blockade of GAPDH-Siah binding by deprenyl in vitro requires the presence of NAD+, which physiologically interacts with the Rossman fold (MR Hara, A Sawa, and SH Snyder: unpublished data). These observations raise the possibility that drugs mimicking GOSPEL might exert neuroprotective actions similar to those of deprenyl.

Heretofore, studies of the NO-GAPDH-Siah/GOSPEL cascade have focused upon cyto/neurotoxicity. However, it is likely that this signaling system possesses physiologic roles. Thus, GAPDH-GOSPEL binding is detectable in untreated cerebral cortical cultures with the binding diminished in nNOS deleted cultures or cultures treated with the NMDA antagonist MK801 (data not shown). Nuclear translocation of GAPDH may convey signals from neuronal activity to epigenetic controls of gene transcription by modulating p300/CBP-mediated histone acetylation (Sen et al., 2008), which may be regulated by GAPDH-GOSPEL interactions.

EXPERIMENTAL PROCEDURES

Unless otherwise noted, all data are representative of 3 individual experiments.

Chemicals, antibodies, plasmids, overexpression and RNAi-virus

Unless otherwise noted, chemicals were purchased from Sigma. Protein G and A agaroses were purchased from Oncogene. Antibodies were obtained from the following companies: anti-GAPDH monoclonal antibody from Biogenesis; anti-histone H2B antibody and anti-actin antibody from Upstate; anti-HA antibody from Babco; anti-Myc antibody from Calbiochem; anti-nNOS antibody from BD Pharmingen anti-HA antibody from Covance and anti-Siah antibody from Santa Cruz; anti-GFP antibody, anti-mouse Ig conjugated to FITC, and anti-rabbit Ig conjugated to rhodamine from Molecular Probes. Polyclonal antibody against GOSPEL was generated with the following procedures: GST-tagged GOSPEL was produced in E. coli, purified through glutathione-sepharose beads (Pharmacia Biotech, Piscataway, NJ), and used for antigen. Antisera were produced by a service of Research Genetics, and the sera were immunopurified. Constructs expressing site-directed or deletion mutant proteins were prepared according to the published protocol (Ho et al., 1989).

GOSPEL RNAi mediated by a lentiviral system (target sequence: 5′-AAGGCTCTGATTGAGCAGAAG-3′) was generated as follows: the target sequences were cloned in the pFUGW vector, and this construct was transfected in HEK293FT cells along with two other helper/packaging vectors (Δ8.9 and VSVg constructs) to produce lentiviral particles. For the production of control lentivirus, FUGW vector was transfected into HEK293FT cells along with two other helper/packaging constructs. Viral production was allowed to take place for 48-72 h inside HEK293 FT cells, and the supernatant was collected and ultracentrifuged to bring down viral particles, which were resuspended into OPTI-MEM. About 106-107 pfu/ml viruses were infected in primary neurons for 24 h. Viral expression was confirmed by observing GFP encoded in pFUGW backbone, 5 days after infection. Wild-type HA-GOSPEL and HA-GOSPEL-ΔN200 expression by a lentiviral system was prepared as follows: both inserts were cloned in pENTR/D-TOPO vector (invitrogen), and then inserted in pLenti4/TO/V5-DEST vector (invitrogen) individually by homologous recombination (according to the manufacturer's protocol). The final constructs were transfected in HEK293T cells along with two other helper/packaging vectors (Δ8.9 and VSVg constructs), and the supernatant was collected and ultracentrifuged to bring down viral particles, which were resuspended into OPTI-MEM. About 107-108 pfu/ml viruses were infected in primary neurons for 24 h. Viral expression was confirmed by doing Western blotting with an HA-antibody 5 days after infection.

Yeast two-hybrid and cDNA library screenings

The N-terminal (amino acids 1-150) of rat GAPDH open reading frame were cloned into yeast expression vector pPC97, containing the Gal4 DNA binding domain. These constructs were used for the screening of a rat hippocampal cDNA library cloned into pPC86, containing the Gal4 transactivation domain. An adult rat brain cDNA library in lambda ZAPII vector (Stratagene) was screened using the yeast two-hybrid fragment for a portion of GOSPEL open reading frame, labeled with [32P]dCTP using a random priming DNA labeling kit (Boehringer-Mannheim). A total of 1 × 106 clones were screened, yielding 61 overlapping clones.

Northern Blotting and in situ hybridization

Rat GOSPEL cDNA fragment utilized as a probe was labeled with [32P]dCTP using the High Prime DNA-labeling system (Roche Diagnostics), and Northern hybridization was performed at 68°C for 2 h in QuikHyb solution (Stratagene) with a tissue mRNA blot membrane (CLONTECH) (Burnett et al., 1998).

Biochemical studies

In vitro binding experiments were performed according to the published protocol with glutathione-sepharose (Bae et al., 2005; Kamiya et al., 2005). Co-immunoprecipitation and Western blotting were conducted as published previously (Bae et al., 2005; Kamiya et al., 2005). Subcellular fractionation was carried out with Nuclear/Cytosol Fractionation Kit (BioVision). S-nitrosylation biotin switch assay was conducted as published previously (Forrester et al., 2007; Jaffrey and Snyder, 2001). Trans-nitrosylation assay was performed as follows: purified wild-type GAPDH (1.5 μg) purchased from Sigma was incubated with 200 μM GSNO at 37°C for 1 h. The whole reaction mixture was then passed through a desalting column (Pierce) to remove free GSNO. S-nitrosylation of GAPDH was confirmed by biotin switch assay. For the trans-nitrosylation reaction, 0.1, 1.0 or 2.5 μg of GST-GOSPEL were incubated with S-nitrosylated GAPDH in 4°C for 1 h with mild rotation in 1 ml of buffer (50 mM Tris pH 7.4, 150 mM NaCl, 0.1 mg/ml BSA, and 0.1% CHAPS). The whole solution was used for the biotin switch assay to detect S-nitrosylation of GOSPEL protein.

In cell-free binding assay we have purified GAPDH, GOSPEL, and Siah protein separately. GAPDH and GOSPEL were incubated separately with 200 μM GSNO at 37°C for 1 h. The whole reaction mixture was then passed through a desalting column (Pierce) to remove free GSNO. Then SNO-GAPDH and SNO-GOSPEL were mixed 1:1 molar ratio. On top of this mixture, GST-Siah was added in a concentration dependent manner (0-500 nM) and kept at 37°C for 1 h. In another set of experiments we incubated SNO-GADH and Siah along with different concentration of GST-GOSPEL (0-100 nM) at 37°C for 1 h. Then we conducted GST-pull down assays and western blots for GAPDH. After measuring the optical density of GAPDH, we calculated IC50 values for inhibition of binding between GAPDH and GOSPEL by Siah as well as binding between GAPDH and Siah by GOSPEL.

For quantitative PCR total RNA was isolated from granule neuron with the RNeasy mini kit (Qiagen) and was reversely transcribed with the Omniscript RT kit (Qiagen). Real-time PCR was performed using SYBR green PCR master mix for OAS1. The primers used for OAS1 amplification are as follows: forward primer for OAS1 is 5′-CCATCCTCAAGTGGACAAGAACTG-3′; reverse primer for OAS1 is 5′-TTGGGCTTTGGGCACCTTC-3′ (Bridge et al., 2003).

Enzymatic assay for GAPDH

GAPDH (10 nM) or S-nitrosylated GAPDH were preincubated with either GOSPEL (100 nM) or Siah (500 nM) at 37 °C for 30 min. S-nitrosylated GOSPEL (100 nM) was also preincubated separately with 10 nM GAPDH or S-nitrosylated GAPDH in the presence or absence of Siah at 37 °C for 30 min. Then “assay mixture” was added in each tube and the incubation continued at 37 °C for 10 min. The assay mixture contained 10 mM sodium pyrophosphate (pH 8.5), 20 mM sodium arsenite, 2 mM NAD+, and 2 mM glyceraldehyde 3-phosphate. Optical density was measured at 340 nm. All values are normalized to control and expressed as arbitary units.

Cell culture and staining

HEK293 cells and HEK293FT cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) with 10% FBS and 2 mM L-glutamine at 37°C with a 5% CO2 atmosphere in a humidified incubator. PC12 cells were maintained in DMEM with 10% FBS, 5% horse serum, 2 mM L-glutamine, and 100 U/ml PS in the same environment. Primary cortical neurons were prepared from fetal mice (14-day gestation) derived from wild-type and nNOS knockout mice, and cultured in Neurobasal media supplemented with B27, 2 mM L-glutamine, and 100 U/ml PS at 37°C with 5% CO2 atmosphere in a humidified incubator. Cerebellar granule neurons were prepared from neonatal mice and cultured in Basal Eagle Medium (BEM) containing 10% FBS, 25 mM KCl, and 2 mM L-glutamine. Immunocytochemistry using confocal microscopy was performed as described (Sawa et al., 1999). Confocal microscropy images were obtained using a Zeiss Meta Confocal System. For neuron cultures anti-GFP antibody was used to enhance the signal from transfected cells.

Measurement of NMDA-induced neurotoxicity in primary neurons

To activate NMDA receptors in neurons, 8-10-day-old cultures (DIC 8-10) were treated with Mg2+ free Earle's Balanced Salt Solution (EBSS) containing 300 μM NMDA and 5 μM glycine for 10 min.

Three days prior to NMDA receptor activation, cerebellar granule neurons were transfected with plasmids as follows: after pre-incubation of cells with Neurobasal (Gibco BRL) including B27 for 24 h from DIV 5, neurons were transfected with 1 μg of GFP construct and a total of 3 μg of varied combinations of plasmids using lipofectamine 2000. The molar ratio of expression constructs to GFP plasmid was 3:1. Using fluorescent microscopy with a digital camera, we captured images of more than 20 fields per preparation, which were randomly chosen in a blind manner. GFP positive neurons were tallied in each field and added together to determine the percentage of viable cells compared to control.

Three days prior to NMDA receptor activation, RNAi-lentivirus was infected into granule or cortical neurons. Viability of neurons was assayed 12 h or 24 h after exposure to NMDA as follows: cells were washed with PBS and incubated in 1 μg/ml propidium iodide for 10 min (dead cells are stained in red). After extensive washing to remove non-specifically attached propidium iodide to cell debris by PBS, neurons were then fixed in 4% paraformaldehyde in PBS and stained with DAPI to visualize the total cell population. As the majority of neurons were infected, the ratio of propidium iodide-stained cells to DAPI-stained cells was employed to reflect toxicity.

Measurement of nitric oxide species

To measure reactive nitric oxide level inside cells, we used 4,5 diamino fluorescein diacetate (DAF-FM, Molecular probes), a cell permeable derivative of the indicator DAF-2 whose fluorescence reflects the level of endogenous nitric oxide (Choi et al., 2000; Chvanov et al., 2006). Briefly, neurons were washed once with Hanks Balanced Salt Solution (HBSS) and then were loaded with 5 μM DAF-FM in HBSS and incubated at 37°C with 5% CO2 atmosphere in a humidified incubator for 60 min. NMDA (300 μM) and glycine (5 μM) were added to the cells and incubated for another 10 min. Cells were washed, harvested in HBSS and fluorescence was measured in a fluorimeter utilizing excitation 485 nm and emission 530 nm. DAF-2 fluorescence was also detected using a laser scanning confocal microscope (Zeiss Meta).

Animals and MPTP Treatment

All experiments were approved and conformed to the guidelines set by the Institutional Animal Care Committee. Eight-week-old male CD1 mice (The Jackson Laboratory) were used. Mice received four i.p. injections of MPTP-HCl (20 mg/kg free base; Sigma) in saline at 2-h intervals and were sacrificed after 16 h and 24 h after the first injection (n = 5). Control mice received saline only. In each case the striatum was isolated and was used for imunoprecipitation and S-nitrosylation experiments (Hara et al., 2006b).

Stereotaxic injection into intact mice

Adult male C57BL/6 mice (20-25 g; Charles River, Wilmington, MA) were used for NMDA mediated cytotoxicity measurement. Animal protocols, approved by the Institutional Animal Care and Use Committee of Johns Hopkins University, were used in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. Animal well being was determined by monitoring the weight and rectal temperature before the surgical procedure. Mice were anesthetized with 3.0% isoflurane, maintained with 1.0% isoflurane and mounted on a stereotaxic frame (Stoelting Co., Wood Dale, IL). The skull was exposed and 5.0 μl (107-108 pfu/ml) of viral particles of either full length GOSPEL (n=8) or delta-N200 GOSPEL (n=9) protein was slowly injected into the cortex (anterior 0.5 mm, lateral 3.5 mm from bregma, and ventral 1.0 mm relative to dura) over a period of 20 min with the help of a 5.0 μl Hamilton® syringe, and the needle was left in place for additional 5 min. Seven days after viral infection, overexpressed full length GOSPEL or delta-N200 GOSPEL in coronal sections were detected by western blot and immunohistochemistry with anti-HA antibody (1:200). On day 8, 15 nmol NMDA was slowly injected at the same location with 1.0 μl Hamilton® syringe. After each injection, mice were placed in a thermoregulated chamber maintained at 31 ±0.5°C and returned to their cages after full recovery from anesthesia. The rectal temperatures were monitored and maintained at 37.0 ± 0.5 °C during the experimental procedure.

NMDA-induced lesion quantification

At 24 h post-NMDA injection, mice were trancardially perfused with 0.1 M PBS and fixed with 4% PFA. Brains were harvested and soaked in 4% PFA overnight, then equilibrated with 30% sucrose. Sequential brain sections of 25 μm obtained on cryostat were stained with cresyl violet to estimate the lesion volume as described previously (Ahmad et al., 2006; Ahmad et al., 2007). One-way ANOVA followed by Tukey's post-hoc analysis was used to calculate the difference between the groups.

Supplementary Material

01

ACKNOWLEDGEMENTS

This work was supported by USPHS grants MH-084018 and MH-069853 (A.S.); DA-00266 (S.H.S.), Research Scientist Award DA-00074 (S.H.S); and grants from the Stanley, NARSAD, CHDI, and S-R foundations (A.S.). We thank Yukiko L. Lema for preparing figures and organizing the manuscript. We appreciate technical assistance by Mr. S. Seshadri, Mr. J. Park, Ms. X. Luo, and Ms. L. Hanle.

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

REFERENCES

  • Ahmad AS, Zhuang H, Echeverria V, Dore S. Stimulation of prostaglandin EP2 receptors prevents NMDA-induced excitotoxicity. J Neurotrauma. 2006;23:1895–1903. [PubMed]
  • Ahmad M, Ahmad AS, Zhuang H, Maruyama T, Narumiya S, Dore S. Stimulation of prostaglandin E2-EP3 receptors exacerbates stroke and excitotoxic injury. J Neuroimmunol. 2007;184:172–179. [PMC free article] [PubMed]
  • Bae BI, Hara MR, Cascio MB, Wellington CL, Hayden MR, Ross CA, Ha HC, Li XJ, Snyder SH, Sawa A. Mutant huntingtin: nuclear translocation and cytotoxicity mediated by GAPDH. Proc Natl Acad Sci U S A. 2006;103:3405–3409. [PubMed]
  • Bae BI, Xu H, Igarashi S, Fujimuro M, Agrawal N, Taya Y, Hayward SD, Moran TH, Montell C, Ross CA, et al. p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron. 2005;47:29–41. [PubMed]
  • Benhar M, Stamler JS. A central role for S-nitrosylation in apoptosis. Nat Cell Biol. 2005;7:645–646. [PubMed]
  • Bonfoco E, Krainc D, Ankarcrona M, Nicotera P, Lipton SA. Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. Proc Natl Acad Sci U S A. 1995;92:7162–7166. [PubMed]
  • Bridge AJ, Pebernard S, Ducraux A, Nicoulaz AL, Iggo R. Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet. 2003;34:263–264. [PubMed]
  • Burnett PE, Blackshaw S, Lai MM, Qureshi IA, Burnett AF, Sabatini DM, Snyder SH. Neurabin is a synaptic protein linking p70 S6 kinase and the neuronal cytoskeleton. Proc Natl Acad Sci U S A. 1998;95:8351–8356. [PubMed]
  • Carlile GW, Chalmers-Redman RM, Tatton NA, Pong A, Borden KE, Tatton WG. Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer. Molecular pharmacology. 2000;57:2–12. [PubMed]
  • Choi YB, Tenneti L, Le DA, Ortiz J, Bai G, Chen HS, Lipton SA. Molecular basis of NMDA receptor-coupled ion channel modulation by S-nitrosylation. Nat Neurosci. 2000;3:15–21. [PubMed]
  • Chuang DM, Hough C, Senatorov VV. Glyceraldehyde-3-phosphate dehydrogenase, apoptosis, and neurodegenerative diseases. Annu Rev Pharmacol Toxicol. 2005;45:269–290. [PubMed]
  • Chvanov M, Gerasimenko OV, Petersen OH, Tepikin AV. Calcium-dependent release of NO from intracellular S-nitrosothiols. EMBO J. 2006;25:3024–3032. [PubMed]
  • Dawson VL, Kizushi VM, Huang PL, Snyder SH, Dawson TM. Resistance to neurotoxicity in cortical cultures from neuronal nitric oxide synthase-deficient mice. J Neurosci. 1996;16:2479–2487. [PubMed]
  • Forrester MT, Foster MW, Stamler JS. Assessment and application of the biotin switch technique for examining protein S-nitrosylation under conditions of pharmacologically induced oxidative stress. J Biol Chem. 2007;282:13977–13983. [PubMed]
  • Hara MR, Agrawal N, Kim SF, Cascio MB, Fujimuro M, Ozeki Y, Takahashi M, Cheah JH, Tankou SK, Hester LD, et al. S-nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah1 binding. Nat Cell Biol. 2005;7:665–674. [PubMed]
  • Hara MR, Cascio MB, Sawa A. GAPDH as a sensor of NO stress. Biochim Biophys Acta. 2006a;1762:502–509. [PubMed]
  • Hara MR, Thomas B, Cascio MB, Bae BI, Hester LD, Dawson VL, Dawson TM, Sawa A, Snyder SH. Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proc Natl Acad Sci U S A. 2006b;103:3887–3889. [PubMed]
  • Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene. 1989;77:51–59. [PubMed]
  • Jaffrey SR, Snyder SH. The biotin switch method for the detection of S-nitrosylated proteins. Sci STKE. 2001;2001:PL1. [PubMed]
  • Kamiya A, Kubo K, Tomoda T, Takaki M, Youn R, Ozeki Y, Sawamura N, Park U, Kudo C, Okawa M, et al. A schizophrenia-associated mutation of DISC1 perturbs cerebral cortex development. Nat Cell Biol. 2005;7:1167–1178. [PubMed]
  • Kim WK, Choi YB, Rayudu PV, Das P, Asaad W, Arnelle DR, Stamler JS, Lipton SA. Attenuation of NMDA receptor activity and neurotoxicity by nitroxyl anion, NO. Neuron. 1999;24:461–469. [PubMed]
  • Nagy E, Rigby WF. Glyceraldehyde-3-phosphate dehydrogenase selectively binds AU-rich RNA in the NAD(+)-binding region (Rossmann fold) J Biol Chem. 1995;270:2755–2763. [PubMed]
  • Sawa A, Wiegand GW, Cooper J, Margolis RL, Sharp AH, Lawler JF, Jr., Greenamyre JT, Snyder SH, Ross CA. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat Med. 1999;5:1194–1198. [PubMed]
  • Sen N, Hara MR, Kornberg MD, Cascio MB, Bae BI, Shahani N, Thomas B, Dawson TM, Dawson VL, Snyder SH, Sawa A. Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis. Nat Cell Biol. 2008;10:866–873. [PMC free article] [PubMed]
  • Sirover MA. New insights into an old protein: the functional diversity of mammalian glyceraldehyde-3-phosphate dehydrogenase. Biochimica et biophysica acta. 1999;1432:159–184. [PubMed]
  • Sirover MA. New nuclear functions of the glycolytic protein, glyceraldehyde-3-phosphate dehydrogenase, in mammalian cells. Journal of cellular biochemistry. 2005;95:45–52. [PubMed]
  • Takahashi H, Shin Y, Cho SJ, Zago WM, Nakamura T, Gu Z, Ma Y, Furukawa H, Liddington R, Zhang D, et al. Hypoxia enhances S-nitrosylation-mediated NMDA receptor inhibition via a thiol oxygen sensor motif. Neuron. 2007;53:53–64. [PMC free article] [PubMed]
  • Tatton W, Chalmers-Redman R, Tatton N. Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B. J Neural Transm. 2003;110:509–515. [PubMed]
  • Waldmeier PC, Boulton AA, Cools AR, Kato AC, Tatton WG. Neurorescuing effects of the GAPDH ligand CGP 3466B. J Neural Transm Suppl. 2000:197–214. [PubMed]